Royalty Report: Drugs, Cancer, Disease – Collection: 27784

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27784

License Grant
Licensor established a drug development collaboration with licensee, a biotechnology company committed to the development of cancer therapeutics for patients with drug resistant and metastatic cancers, to co-develop and commercialize OGX-011, an anti-cancer antisense drug that targets clusterin.  In July 2008, the agreement was amended to which licensee became solely responsible for the costs, development and commercialization of OGX-011.  In exchange, licensee agreed to pay licensor royalties on sales of OGX-011 and to share consideration received from licensing OGX-011 to a third party, except for consideration licensee receives for the fair market value of equity and reimbursement of research and development expenses.

Under the amended Agreement, licensor assigned to licensee rights in the patents claiming the composition and therapeutic methods of using OGX-011 and granted licensee a worldwide, nonexclusive License to know-how and patents covering core antisense technology and manufacturing technology solely for use with OGX-011.  The key product-related patent that was assigned to licensee was U.S. Patent number 6,900,187 having an expiration date of at least 2020; and the key core antisense technology patents that were Licensed are U.S. Patent number 7,919,472 having an expiration date of 2026 and its foreign equivalents pending in Australia, Canada, the European Patent Convention and Japan.  

In December 2009, licensee granted sublicensee the exclusive worldwide right and License to develop and commercialize any products containing OGX-011 and related compounds, with licensee having an option to co-promote OGX-011 in the United States and Canada.

License Property
In August 2003, licensor and licensee entered into a separate collaboration and License Agreement for the development of a second-generation antisense anti-cancer drug, OGX-225.

In January 2005, licensor entered into a further Agreement with OncoGenex to allow for the development of an additional second-generation antisense anti-cancer drug. In April 2005, licensee selected OGX-427 to develop under the collaboration.

Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 27866

License Grant
In 2001 an original License between two co-discovering companies relative to the cancer treatment OGX-011 (antisense therapeutic) was executed.

Update:  in December 2009 the Licensee entered into a global licensing and partnership agreement with a third company.  The Licensor in the transaction above continues to receive payments from the secondary License too.

Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property:
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as
permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes:
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to: Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.